
Ask a doctor about a prescription for APIXABAN SANDOZ 5 mg FILM-COATED TABLETS
Package Leaflet: Information for the User
Apixaban Sandoz 5 mg Film-Coated Tablets EFG
apixaban
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack and other information
This medicine contains the active substance apixaban and belongs to a group of medicines called anticoagulants. This medicine helps to prevent the formation of blood clots by blocking Factor Xa, an important element in the blood clotting process.
This medicine is used in adults:
Do not take Apixaban Sandoz if:
Warnings and precautions
Tell your doctor, pharmacist, or nurse before you start taking this medicine if you have any of these conditions:
This medicine will be used with caution in patients with signs of liver function alteration,
Be careful with apixaban
If you need to have surgery or a procedure that may cause bleeding, your doctor will tell you to temporarily stop taking this medicine for a period of time. If you are not sure if a procedure may cause bleeding, ask your doctor.
Children and adolescents
This medicine is not recommended for children and adolescents under 18 years of age.
Other medicines and Apixaban Sandoz
Tell your doctor, pharmacist, or nurse if you are using, have recently used, or might use other medicines.
Some medicines may increase the effects of apixaban and some medicines may decrease its effects. Your doctor will decide if you should be treated with apixaban if you are taking these medicines and if you should be kept under closer observation.
The following medicines may increase the effects of apixaban and increase the possibility of unwanted bleeding:
The following medicines may reduce the ability of apixaban to prevent blood clots.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
The effects of this medicine on pregnancy and the fetus are not known. You should not take this medicine if you are pregnant. Tell your doctor immediatelyif you become pregnant while taking this medicine.
It is not known if this medicine is excreted in human milk. Ask your doctor or pharmacist for advice before taking this medicine during breastfeeding. They will tell you whether to interrupt breastfeeding or whether to stop or not start taking this medicine.
Driving and using machines
Apixaban has no influence on the ability to drive or use machines.
Apixaban Sandoz contains lactose (a type of sugar) and sodium
If your doctor has told you that you have an intolerance to some sugars, consult with them before taking this medicine.
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is essentially “sodium-free”.
Always take this medicine exactly as your doctor or pharmacist has told you. If you are not sure, check with your doctor, pharmacist, or nurse.
Dose
Take the tablet with water. Apixaban can be taken with or without food.
Try to take the tablets at the same time each day to achieve a better effect of the treatment.
If you have difficulty swallowing the tablet whole, talk to your doctor about other possible ways to take apixaban. The tablet can be crushed and mixed with water, 5% glucose in water, apple juice, or apple puree, immediately before taking it.
Instructions for crushing:
If necessary, your doctor may also administer the crushed apixaban tablet mixed in 60 ml of water or 5% glucose in water through a nasogastric tube.
Take Apixaban Sandoz according to the following recommendations:
To prevent the formation of a blood clot in the heart in patients with an irregular heartbeat and at least one additional risk factor
The recommended dose of apixaban is one 5 mg tablet twice a day.
The recommended dose of apixaban is one 2.5 mg tablet twice a day if:
The recommended dose is one tablet twice a day, e.g., take one tablet in the morning and one in the evening.
Your doctor will tell you how long to continue the treatment.
To treat blood clots in the veins of the legs and in the blood vessels of the lungs
The recommended dose of apixaban is two 5 mg tablets twice a day for the first 7 days, e.g., two tablets in the morning and two tablets in the evening.
After 7 days, the recommended dose of apixaban is one 5 mg tablet twice a day, e.g., one tablet in the morning and one in the evening.
To prevent blood clots from happening again after 6 months of treatment
The recommended dose of apixaban is one 2.5 mg tablet twice a day, e.g., one tablet in the morning and one in the evening.
Your doctor will tell you how long to continue the treatment.
Your doctor may change your anticoagulant treatment as follows:
Switching from Apixaban Sandoz to other anticoagulant medicines
Stop taking Apixaban Sandoz. Start treatment with other anticoagulant medicines (e.g., heparin) at the time you would have taken the next Apixaban Sandoz tablet.
Switching from other anticoagulant medicines to Apixaban Sandoz
Stop taking other anticoagulant medicines. Start treatment with Apixaban Sandoz at the time you would have taken the next dose of an anticoagulant medicine, and then continue as usual.
Switching from a treatment with anticoagulants that contain Vitamin K antagonists (e.g., warfarin) to Apixaban Sandoz
Stop taking the medicine that contains a Vitamin K antagonist. Your doctor will need to perform blood tests and tell you when to start taking Apixaban Sandoz.
Switching from Apixaban Sandoz to a treatment with anticoagulants that contain Vitamin K antagonists (e.g., warfarin)
If your doctor tells you to start taking a medicine that contains a Vitamin K antagonist, continue taking Apixaban Sandoz for at least 2 days after your first dose of the medicine that contains a Vitamin K antagonist. Your doctor will need to perform blood tests and tell you when to stop taking Apixaban Sandoz.
Patients undergoing cardioversion
If your heartbeat needs to be restored through a process called cardioversion, take this medicine at the times your doctor tells you to prevent blood clots in the blood vessels of the brain and other blood vessels in the body.
If you take more Apixaban Sandoz than you should
Tell your doctor immediatelyif you have taken a dose higher than the prescribed dose of this medicine. Take the package of the medicine to your doctor, even if there are no tablets left.
If you take more Apixaban Sandoz than the recommended dose, you may increase the risk of bleeding. If bleeding occurs, surgery, blood transfusions, or other treatments that can reverse the anti-factor Xa activity may be necessary.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medicine and the amount taken.
If you forget to take Apixaban Sandoz
Take the dose as soon as you remember and:
If you are not sure what to do or if you have forgotten to take more than one dose,ask your doctor, pharmacist, or nurse.
If you stop taking Apixaban Sandoz
Do not stop taking this medicine without talking to your doctor first, because the risk of developing a blood clot may be greater if you stop the treatment too soon.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them. The most frequent adverse effect of this medicine is bleeding, which can put the patient's life at risk and requires immediate medical attention.
The following adverse effects have been reported when taking apixaban to prevent the formation of blood clots in the heart in patients with irregular heart rhythm and at least one additional risk factor.
Frequent Adverse Effects (may affect up to 1 in 10 people)
Uncommon Adverse Effects (may affect up to 1 in 100 people)
Rare Adverse Effects (may affect up to 1 in 1,000 people)
Very Rare Adverse Effects (may affect up to 1 in 10,000 people)
Unknown Frequency (cannot be estimated from available data)
The following adverse effects have been reported when taking apixaban to treat or prevent blood clots from forming again in the veins of the legs and in the blood vessels of the lungs.
Frequent Adverse Effects (may affect up to 1 in 10 people)
Uncommon Adverse Effects (may affect up to 1 in 100 people)
Rare Adverse Effects (may affect up to 1 in 1,000 people)
Unknown Frequency (cannot be estimated from available data)
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect that is not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date stated on the carton and on each blister, after "EXP". The expiration date is the last day of the month indicated.
This medicine does not require special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Deposit the packaging and any unused medicines in the pharmacy's SIGRE collection point. If in doubt, ask your pharmacist how to dispose of the packaging and any unused medicines. This will help protect the environment.
Composition of Apixaban Sandoz
See section 2 "Apixaban Sandoz contains lactose (a type of sugar) and sodium".
Appearance of the Product and Package Contents
Apixaban Sandoz 5 mg are film-coated tablets (tablets) pink, oval, biconvex, engraved with "AX" on one side and with "5" on the other side, with a width of 5.0 - 5.7 mm and a length of 9.6 - 10.3 mm.
The product is available in:
Alu-PVC/PVdC blisters in packs of 10, 12, 14, 20, 28, 30, 56, 60, 100, 168, 180, and 200 film-coated tablets.
Perforated unit-dose Alu-PVC/PVdC blisters in packs of 20x1, 30x1, 60x1, 100x1, and 168x1, and 180x1 film-coated tablets.
HDPE/PP bottle of 200 film-coated tablets.
Not all pack sizes may be marketed.
Patient Information Card: Information Management
Inside the Apixaban Sandoz package, along with the leaflet, you will find a Patient Information Card or your healthcare professional may give you a similar card.
This Patient Information Card includes useful information for you and will alert other doctors that you are being treated with Apixaban Sandoz. You must keep this card with you at all times.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder
Sandoz Farmacéutica, S.A.
Centro Empresarial Parque Norte
Edificio Roble
C/ Serrano Galvache, 56
28033 Madrid
Spain
Manufacturer
Lek Pharmaceuticals d.d.
Verovskova ulica 57
1526 Ljubljana
Slovenia
or
Lek S.A.
Ul. Podlipie 16
95 010 Strykow
Poland
This medicine is authorized in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) under the following names:
Netherlands: Apixaban Sandoz 5 mg, filmomhulde tabletten
Austria: Apixaban Sandoz 5 mg - Filmtabletten
Belgium: Apixaban Sandoz 5 mg filmomhulde tabletten
Czech Republic: Apixaban Sandoz
Denmark: Apixaban Sandoz
Greece: Apixaban/Sandoz F.C. TAB 5 mg
Finland: Apixaban Sandoz
France: APIXABAN SANDOZ 5 mg, comprimé pelliculé
Hungary: Apixaban Sandoz 5 mg filmtabletta
Ireland: Apixaban Rowex 5 mg film-coated tablets
Iceland: Apixaban Sandoz
Italy: Apixaban Sandoz
Norway: Apixaban Sandoz
Portugal: Apixaban Sandoz
Sweden: Apixaban Sandoz
Slovakia: Apixaban Sandoz 5 mg
United Kingdom (Northern Ireland): Apixaban Sandoz 5 mg Film coated tablets
Date of the last revision of this leaflet:February 2024.
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for APIXABAN SANDOZ 5 mg FILM-COATED TABLETS – subject to medical assessment and local rules.